Background. With >1.4 million cases in the United States reported to the Centers for Disease Control and Prevention in 2012, Chlamydia trachomatis infection is a major public health concern. We examined the impact of a C trachomatis vaccination program using a decision-analysis model to estimate the effects of vaccination on C trachomatis-associated costs and morbidity.
Chlamydia trachomatis is the most common bacterial sexually transmitted infection (STI) reported in the US population [1] , which is a major health concern. In 2010, >1.3 million infections in the United States were reported to the Centers for Disease Control and Prevention (CDC) [2] . The actual incidence of C trachomatis infection in the United States is estimated to be 2.8 million cases annually, because many infections are not detected or reported [3] . In 2013, the estimated direct lifetime cost of treatment for all people affected was >$500 million, excluding the costs of screening programs [4] .
Because the majority of women with genital chlamydial infection are asymptomatic [1] , the largest burden from C trachomatis infection is in women whose untreated genital infection can result in pelvic inflammatory disease (PID), which can cause infertility, ectopic pregnancy, and chronic pelvic pain [5, 6] .
In addition, infants born to women with untreated chlamydial infection might acquire infection during delivery, which can lead to neonatal conjunctivitis and respiratory tract infection [1] . Untreated infection in men can lead to urethritis, epididymitis, and proctitis. Thus, screening is needed to identify and treat infections before complications develop [7] . Routine screening for C trachomatis in pregnant women in the United States has been recommended by the CDC since 1993 [8] .
Previous studies in our laboratory (based on our hypothetical decision-analysis model) revealed that the total annual healthcare cost associated with C trachomatis infection is greater when a screening program is implemented in both high-and low-burden settings [9] . However, current screening programs are not always effective in decreasing the prevalence of C trachomatis infection [10] , and expanding programs might be too costly for the control of this infection; vaccine development might be necessary for reducing the prevalence of infection with C trachomatis. The literature shows that previous exposure to C trachomatis does not provide significant immunity against reinfection; an effective vaccine against C trachomatis would have to elicit an immune response that is better than that which is elicited by natural infection [11] .
Although immunization is the most efficient means of controlling microbial infection, no C trachomatis vaccine is available at this time [12] . Development and evaluation of a safe vaccine with high efficacy are needed to prevent C trachomatis infection [12] . Several C trachomatis vaccines are under development, but the optimal age for vaccination is unknown [12] . The CDC reported potential cost-effectiveness of a C trachomatis vaccination program starting at 14 years of age for women [13] , but the results of a seroprevalence study in our Brooklyn population suggest that acquisition of C trachomatis in women can occur as early as 11 years of age [14] . In this study, we examined the impact of a potential C trachomatis vaccination program by creating a decision-analysis model to estimate the effects of vaccination, beginning at 9 years of age, on C trachomatis-associated costs and morbidity, as is currently recommended for the human papillomavirus (HPV) vaccine [15] .
METHODS
We developed a decision-analysis Markov model to estimate costs and the health-related impact of a hypothetical vaccination program against C trachomatis in a high-burden setting. The vaccination program included all females aged 9 to 26 years. Pregnant women were screened for C trachomatis. Using outcome data and probabilities from the literature, we predicted the number of cases of C trachomatis infection, the cost to the healthcare system, and associated morbidities. We studied a population of 2 158 117 females (the current approximate number of 9-year-old girls in the US population), with a discount rate of 3%. The 2 comparison arms that we developed were females in the vaccination program and those not in the vaccination program. Costs, infection rates, and morbidities were calculated and compared. This study was exempt from ethical approval because we used existing data or record collection from previous literature that contained nonidentifiable data.
Model Parameters and Primary Analysis
A decision-analysis model using the TreeAge Pro (TreeAge Software, Inc., Williamstown, MA) suite was developed to compare outcome variables in 2 study arms in females aged 9 to 26 years, namely, those in a C trachomatis vaccination program and those not in a C trachomatis vaccination program. In the vaccination program, it was assumed for baseline analysis that 39.7% of the females were vaccinated [16] . This value was chosen on the basis of the HPV vaccination rate. This model predicted the costs and morbidities associated with C trachomatis infection over a 17-year period. End points included direct costs to the healthcare system, PID, rates of C trachomatis infection, rates of vertical mother-to-child transmission, spontaneous abortion, neonatal conjunctivitis, neonatal pneumonia, and preterm delivery. The disease and population parameters were set as point estimates using 2015 US dollars.
The model was run with a baseline vaccine efficacy of 90%, the approximate efficacy of the HPV vaccination that decreases over the 17-year period to 0% [17] . Alternative efficacy and coverage rates were also examined to understand the changes in outcomes. Coverage levels of 60% and 20% and an efficacy rate of 80% were examined in this model.
Costs and Disease Parameters
This decision-analysis model examined direct costs to the US healthcare system associated with chlamydial infection and its sequelae in females between the ages of 9 and 26 years. The model included the cost of vaccination, treatment of C trachomatis infection, PID, premature delivery, vertical transmission leading to neonatal pneumonia, neonatal conjunctivitis, and spontaneous abortion. These costs were derived from current Medicaid reimbursement rates. Costs reported for the vaccination arm were inclusive of savings associated with decreased C trachomatis morbidities.
C trachomatis infection was set at a prescreening prevalence of 6.7% [12] , screening using a nucleic acid amplification test for C trachomatis was set to a sensitivity of 98% [18] , and treatment success was set to 97% [19] . PID rates were input at 27% [20] , with chlamydia-associated infertility (unrelated to PID) set at 0.845% [21] . Lifetime cost associated with PID was set to $10 420 [22, 23] , cost to screen for chlamydia was set at $33.48 (Medicaid reimbursement rate), and cost to treat chlamydial infection was set at $1.86 per patient [24] . Costs and additional disease parameters are shown in Table 1 .
Epidemiological Model
A cohort of 2 158 117 females aged 9 to 26 years was considered. Identical cohorts of females were placed into the vaccination-program and non-vaccination-program arms. Individuals were then organized on the basis of their C trachomatis status, PID history, and pregnancy status. Each of these subgroups then could progress to developing C trachomatis infection or PID or becoming pregnant. C trachomatis-positive individuals in either group could be asymptomatic, treated, or lost to follow-up. If lost to follow-up, or in the event of treatment failure, individuals might have been free of sequelae or entered onto a morbidity branch, including that for vertical transmission, PID, or spontaneous abortion. The same general principles applied to pregnancy and PID status. Those who did not have PID but who later tested positive for C trachomatis might have gone on to develop PID and experience treatment or sequelae. These individuals might also have become pregnant and experienced spontaneous abortion, premature delivery, vertical transmission, neonatal pneumonia, or neonatal conjunctivitis. Multiple end points could exist in a single individual. As hypothetical cohort members entered different branches, they accrued costs associated with screening and each aforementioned end point. Rates of morbidity and costs to the healthcare system were recorded as they were accumulated. The decision-analysis model trees are presented in Figures 1 and 2 .
Sensitivity Analysis
Sensitivity analyses were run for all variables in the model. Rates for the model variables were distributed either across published ranges or set to ±50% of base-case parameters. Costs and health-related outcomes for the vaccination and nonvaccination scenarios were gathered each time a variable was altered. For example, the cost of a vaccination program was predicted when the cost of vaccination was set at ±50% of the base variable used in the primary analysis to offer a greater range of possibility when using results from the model. More in-depth analyses were performed for those variables with the greatest effect, including the rates of C trachomatis infection, cost of C trachomatis screening/vaccination, and rates of screening coverage. A multiway probabilistic sensitivity (Monte Carlo) analysis, in which those 3 variables were varied simultaneously across distribution tables, was conducted also. A triangular distribution was created; the most likely sampled values were the base-case variables, and ranges were set to ±50% of the base variable. The distribution used for the screening coverage variable in the Monte Carlo simulation was set between 50% and 100%. The analysis consisted of 100 runs; each run contained 100 000 simulations. The aggregate of the 100 runs was used to report the median, mean, and interquartile ranges for the Monte Carlo simulation results.
RESULTS

Base-Case Scenario (Main Analysis)
In our base-case analysis, we found a net increase in cost of $41.77 million with a vaccination program, including 34 088 cases of C trachomatis infection and 5976 cases of PID averted. Trends changed as expected as vaccine coverage and efficacy were set across the aforementioned ranges. At no point in the primary analysis scenarios did the vaccination program become cost-saving; however, a large decrease in the numbers of cases of C trachomatis infection and spontaneous abortion remained throughout. Results are shown in Tables 2 and 3 .
Best-and worst-case scenarios for vaccination were developed to test the robustness of the model's findings. For these 2 scenarios, the cost of vaccination, prevalence of C trachomatis infection, vaccine efficacy, and vaccine coverage were altered to make the vaccine look maximally and minimally effective, respectively (Table 3 ). In the worst-case scenario, vaccination continued to avert significant morbidity and death, although it was increasingly expensive. In the best-case scenario, vaccination proved to be cost-saving (Table 3) .
Sensitivity Analysis
Parameters that affect the health-related outcomes and costs associated with chlamydia in the screening and nonscreening scenarios were varied by ±50% of their base value, across published ranges, or to encompass a wide variety of values. All variables were tested, and those with a significant effect on outcomes are reported here. When chlamydia prevalence was raised by 50%, the vaccination program proved cost-saving by $111.54 million; otherwise, trends remained similar to those found in the primary analysis for all sensitivity analyses. In this scenario, the vaccination program was $21 million more expensive than the nonvaccination program (Table 4) .
Monte Carlo Multiway Probabilistic Analysis
The median cost associated with the vaccination program was $721 million (mean, $718 million; interquartile range, $602 million to $828 million). In the 100 runs, we found only a few iterations in which the cost of the vaccination program was less than the nonvaccination program ($669 million); in the majority of the scenarios, the cost of the vaccination program was higher than that of the nonvaccination program.
DISCUSSION
On the basis of our virtual decision-analysis model, we estimate that a hypothetical C trachomatis vaccination program for females aged >9 years in the United States would cost $710 million for a cohort of 2 158 117 over a 17-year period, an increase of $41.77 million over the cost of a nonvaccination program ($669 million). In addition, a vaccination program would prevent 34 000 cases of C trachomatis infection and 5976 cases of PID. Overall, results from our analyses revealed that a C trachomatis vaccine would not be cost-saving to the healthcare system, but it could avert significant chlamydia-associated morbidity and death. C trachomatis is a major public health concern in the United States and worldwide; each year, >1.3 million infections in the United States are reported to the CDC, and the estimated incidence is 2.8 million cases annually [1, 2] . Furthermore, C trachomatis infection comes at a high cost to the healthcare system, estimated at more than $500 million [4] . As such, there have been increased investigations into the development of an anti-C trachomatis vaccine and inquiries into the development of screening and vaccination programs.
The results of C trachomatis vaccine-modeling efforts suggest that a successful chlamydia vaccine could be cost-effective [25] . Owusu-Edusei et al [25] determined that a vaccination program might be cost-effective, with an incremental cost-effectiveness ratio of $38 700 per quality-adjusted life year in their primary analysis, and they put forth other plausible scenarios in which a vaccination program could be cost-effective. The authors concluded that the cost of screening and vaccination would be greater than that of not vaccinating and not screening. In addition, significant morbidities were averted in their model [25] .
Although the findings of our study are consistent with those of the aforementioned study [25] , some differences between the methodologies used exist. Owusu-Edusei et al [25] examined females aged 14 to 24 years and used a chlamydia prevalence of 3.2% in their main analysis, and 3.7% was used in additional studies. We examined a wider age range (9-26 years) and focused on a higher-burden setting than they did. Furthermore, our modeling methods differed greatly; in their study, they used a deterministic population-based compartmental model, whereas we used a decision-tree-analysis approach. Last, there was a difference in the range of sensitivity analyses and variables examined.
From our sensitivity analysis, the cost/benefit ratio of a C trachomatis vaccination program depended largely on the burden of C trachomatis infection. Given that with an increase in our baseline prevalence of 50%, the vaccination program became cost-saving, it is likely that other high-burden settings would see similar results. Although C trachomatis infection remains a public health concern, the cost of screening can be high in low-resource settings, and thus, screening might not be a practical recommendation in developing countries.
Recent cost-benefit analyses determined that the total annual cost to the healthcare system is greater when screening programs are implemented, although significant morbidity can be averted [9] . However, not all screening programs effectively decrease the prevalence of C trachomatis, and in certain settings, expanding such programs might be prohibitively costly [26, 27] . Although prenatal screening is a crucial intervention in lowresource areas, countries that do not screen have a high burden of C trachomatis infection (>8%); these countries include the Netherlands (8%) and Ireland (5.6% overall and 9.1% of cases in girls between 16 and 18 years of age) [27, 28] . Thus, on the basis of this information, it is likely that the introduction of a vaccination program to prevent C trachomatis infections is warranted in both low-resource and select well-resourced high-burden settings.
The widespread and accurate description of these costeffectiveness models has become increasingly important with the initiation of phase I clinical trials for a C trachomatis vaccine [29] . More vaccine candidates are expected to enter trials in the near future. This work extends from genital infection to examining the effects of vaccination on ocular infection [29] . Although marketing, efficacy, and means of production are still in debate or under investigation, vaccine development is currently underway [29] .
When discussing the development of a vaccine for an STI, it is important to consider barriers and opposition to other vaccines, including that against HPV. The coverage rate for the HPV vaccine has lagged behind those of many other scheduled vaccines. The barriers are largely social and include lack of insurance coverage and poor knowledge of HPV and the vaccine against it. Concerns regarding long-term safety and effects on future fertility are often cited barriers [30] . In addition, concerns and hesitancy exist in parents [30] ; the notion that offering protection against STIs might lead to increased sexual activity is cited as a factor for poor HPV vaccine coverage. Younger females and males are also less likely to be vaccinated, although these 2 populations would likely benefit largely from STI vaccination [30, 31] . It should be kept in mind that the development of a C trachomatis vaccination program will likely face similar hurdles. The effect this has on coverage was explored in our model by ranging vaccination rates in the sensitivity analyses. Another issue faced by the HPV vaccination, which might or might not influence C trachomatis coverage rates, is vaccination frequency. Vaccination frequency ultimately affects both coverage and efficacy (depending on the number of doses necessary). Our model based coverage estimates on those for the HPV vaccine and used a rate that included only those who receive the full regimen of vaccination [30] . As such, it is true that the model might underestimate true coverage and efficacy rates. It is possible that STI vaccines play an important cost-effectiveness role, even when other treatments or interventions are available [32] . The potential for an STI vaccine will be clear once trial data show its characteristics [32] . As mentioned already, the first vaccine candidate for genital chlamydial infection has entered Phase I trials, and several more are in the pipeline [29, 33] .
The use of novel technological methods will likely result in viable vaccine candidates for other diseases, including gonorrhea and syphilis, in the future [33] . The global STI vaccine roadmap (generated by the World Health Organization and the National Institute of Allergy and Infectious Diseases) outlines key activities for further advancing STI vaccine development and provides a framework for that advancement [29, 33] . Obtaining better data on chlamydia-associated PID, infertility, ectopic pregnancy, and chronic pelvic pain and their costs will be central for encouraging funding for a future vaccine against C trachomatis [29] .
STRENGTHS AND LIMITATIONS
Limitations to this study relate largely to the modeling method chosen. Because of the paucity of data regarding partner infection/ treatment and asymptomatic chlamydia, we were unable to incorporate these variables into the model. In addition, the use of a static decision-analysis model did not enable us to perform a dynamic study of infection in which changes in infection and prevalence rates as the vaccination program progressed could be examined.
However, using this model precluded dynamic study of infection, which would have accounted for changing prevalence and infection rates as the modeled screening program progressed. Chlamydia-related sequelae were applied to cohort members at the time of onset as determined by the model; the model did not factor in duration of infection. Last, because of uncertainty regarding rates of sequelae, the cost-savings might be overestimated.
It should be mentioned also that herd protection was not factored into our Markov model. Vaccination programs provide protection to those immunized and unvaccinated members of the community. The notion of herd immunity should be taken into account for vaccination programs against STIs (eg, HPV, herpes simples viruses 1 and 2, C trachomatis), because humanto-human (1:1) transmission is the primary way of encountering these pathogens. An effective C trachomatis vaccine would work by eradicating or eliminating the pathogen from the genitalia, thus controlling the infectious disease.
Despite its limitations, there are several strengths to this study. We included few calculated estimates as variables; the majority of variables were derived from primary epidemiologic studies or previous cost-effectiveness analyses. Unlike other relatable studies, we examined numerous end points related to C trachomatis infection and report a wide variety of data. In addition, we focused on a high-burden setting with a high prevalence of C trachomatis infection. As such, the results can be generalized to both US and non-US settings in which a high burden of C trachomatis infection exists; a notable exception is the cost to the healthcare system, which varies widely according to location. Last, in our study we were able to see how costs and morbidities change stage by stage over the span of our 17-year study period.
CONCLUSIONS
When a vaccine with known efficacy becomes available for the prevention of C trachomatis, healthcare professionals could consider the expected benefits [34, 35] . It seems likely that C trachomatis vaccines have the greatest potential market because of their high prevalence in some developed countries [32] . Our model estimated that a chlamydia vaccination program in a high-burden US-based population setting would avert significant morbidities but without cost savings for the healthcare system. Our sensitivity analysis showed that this expenditure drops off rapidly as the prevalence of C trachomatis rises. The results of our model provide an approach to both high-resource settings with a goal of decreasing C trachomatis prevalence and low-resource high-burden settings in which a vaccination program might ultimately prove cost-saving.
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